Athenex Announces Potential Price Range for IPO
Athenex expects to price 6 million shares in the range of $11 to $13 apiece for an initial public offering is valued up to more than $89 million.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 167
Juno Therapeutics Sinks Following ASCO Update
Juno Therapeutics aw its shares slide after the company reported updated clinical trial results at the Annual Meeting for the American Society of Clinical Oncology (ASCO).
Aileron Therapeutics Gears Up for IPO
Aileron Therapeutics has filed with the U.S. Securities and Exchange Commission (SEC) for its initial public offering (IPO).
7 ASCO Stocks Moving on Cancer Study News (Updated)
The Annual Meeting for the American Society of Clinical Oncology (ASCO) is currently underway in Chicago, and the health care sector is on the move.
What Analysts Have to Say About Walgreens Ahead of the Merger Deadline
Analysts have taken the perspective that the Walgreens/Rite Aid deal might be too difficult to call correctly, and those covering it generally have created two scenarios about what could happen.
15 Companies Bracing for Big ASCO Reactions
24/7 Wall St. takes a look at the ASCO annual meeting each year and picks out the companies that could have the biggest boom or bust at the conference.
Why Minerva Shares Are Climbing
Minerva Neurosciences has amended its co-development agreement with Janssen Pharma will repurchase all of its shares owned by Johnson & Johnson Innovation.
A New Era of Cancer Research as ASCO Kicks Off
Just ahead of the 2017 annual meeting of the American Society of Clinical Oncology, a new report shows that more than 240 immuno-oncology medicines and vaccines are currently in development.
Why Credit Suisse Sees Insurers Gaining More Than Hospitals
Credit Suisse has raised its price targets for select managed care organizations but remains neutral to cautious on hospital stocks.
Why Analysts Think Protagonist Therapeutics Could Still More Than Double After the News
When companies see their shares rise almost 50%, investors probably just assume the news is from a buyout or a merger. In Tuesday's massive gain in shares of Protagonist Therapeutics, it was that the…
7 Speculative Biotech and Pharma Stocks That Could Still Double (or More)
Here are seven speculative biotech and biohealth stocks where analysts gave huge upside calls during the month of May 2017.
Can Protagonist Therapeutics Stock Still Double After Its Huge Gain?
Protagonist Therapeutics Inc. (NASDAQ: PTGX) saw its shares move up so much on May 30 that some investors probably just assumed this was a takeover or that the company had major news shaking the…
ImmunoGen Rises Following Licensing Update With Sanofi
ImmunoGen watched its stock make a handy gain after the firm announced that had amended its license agreements with Sanofi.
Why Protagonist Therapeutics Shares Are Climbing
Protagonist Therapeutics saw its shares make a solid gain early on Tuesday after the company announced a key worldwide licensing and collaboration agreement with Janssen Biotech.
Top Presentations to Look for at ASCO
The 2017 annual meeting of the American Society of Clinical Oncology (ASCO) runs from June 2 to June 6. The following companies have signaled that they will be presenting data, or data will be…